Bluebird Sickle Cell Gene Therapy Hangs In Balance
Company Probes Causes Of Blood Cancers
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
You may also be interested in...
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.
The news comes less than a week after data partially exonerated its other gene therapy in a cancer scare announced in February.
The jury is still out on the case of MDS and some remaining questions regarding the AML case may still hinder commercial uptake.